Artelo Biosciences (NASDAQ:ARTL) and CSL (OTCMKTS:CSLLY) Financial Contrast

Artelo Biosciences (NASDAQ:ARTL) and CSL (OTCMKTS:CSLLY) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, earnings, dividends and profitability.

Earnings and Valuation

This table compares Artelo Biosciences and CSL’s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artelo Biosciences	N/A	N/A	-$9.29 million	($3.14)	-0.41
CSL	$13.31 billion	6.31	$2.19 billion	N/A	N/A

CSL has higher revenue and earnings than Artelo Biosciences.

Analyst Ratings

This is a summary of current ratings and recommmendations for Artelo Biosciences and CSL, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artelo Biosciences	0	0	1	0	3.00
CSL	0	0	0	0	N/A

Artelo Biosciences presently has a consensus price target of $5.00, indicating a potential upside of 290.63%. Given Artelo Biosciences’ higher possible upside, equities research analysts clearly believe Artelo Biosciences is more favorable than CSL.

Risk and Volatility

Artelo Biosciences has a beta of 1.45, suggesting that its stock price is 45% more volatile than the S&P 500. Comparatively, CSL has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500.

Profitability

This table compares Artelo Biosciences and CSL’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Artelo Biosciences	N/A	-61.68%	-58.15%
CSL	N/A	N/A	N/A

Insider and Institutional Ownership

0.9% of Artelo Biosciences shares are owned by institutional investors. Comparatively, 0.0% of CSL shares are owned by institutional investors. 6.9% of Artelo Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Artelo Biosciences beats CSL on 5 of the 9 factors compared between the two stocks.

About Artelo Biosciences

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for treating breast and prostate cancer, neuropathic and nociceptive pain, and anxiety disorders, including PTSD. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

About CSL

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.